These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30025172)

  • 1. Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration.
    Gava G; Mancini I; Cerpolini S; Baldassarre M; Seracchioli R; Meriggiola MC
    Clin Endocrinol (Oxf); 2018 Dec; 89(6):878-886. PubMed ID: 30025172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition, and Metabolic Profile in Transmen.
    Gava G; Armillotta F; Pillastrini P; Giagio S; Alvisi S; Mancini I; Morselli PG; Seracchioli R; Meriggiola MC
    J Sex Med; 2021 Mar; 18(3):646-655. PubMed ID: 33531255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
    Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
    Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men.
    Jockenhövel F; Bullmann C; Schubert M; Vogel E; Reinhardt W; Reinwein D; Müller-Wieland D; Krone W
    Metabolism; 1999 May; 48(5):590-6. PubMed ID: 10337859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: effect on anthropometric, metabolic and biochemical parameters.
    Pelusi C; Costantino A; Cerpolini S; Pelusi G; Meriggiola MC; Pasquali R
    Int J Androl; 2011 Dec; 34(6 Pt 1):548-55. PubMed ID: 21087288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals.
    Mueller A; Haeberle L; Zollver H; Claassen T; Kronawitter D; Oppelt PG; Cupisti S; Beckmann MW; Dittrich R
    J Sex Med; 2010 Sep; 7(9):3190-8. PubMed ID: 20584125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial.
    Anawalt BD; Amory JK; Herbst KL; Coviello AD; Page ST; Bremner WJ; Matsumoto AM
    J Androl; 2005; 26(3):405-13. PubMed ID: 15867009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations.
    Kamischke A; Heuermann T; Krüger K; von Eckardstein S; Schellschmidt I; Rübig A; Nieschlag E
    J Clin Endocrinol Metab; 2002 Feb; 87(2):530-9. PubMed ID: 11836281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
    Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
    Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception.
    Kamischke A; Venherm S; Plöger D; von Eckardstein S; Nieschlag E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):303-9. PubMed ID: 11232016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
    Anderson RA; Wallace AM; Wu FC
    J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of three different testosterone formulations in female-to-male transsexual persons.
    Pelusi C; Costantino A; Martelli V; Lambertini M; Bazzocchi A; Ponti F; Battista G; Venturoli S; Meriggiola MC
    J Sex Med; 2014 Dec; 11(12):3002-11. PubMed ID: 25250780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in sensitivity and rate of change in body composition: steps toward individualizing transgender care.
    van Velzen DM; Nota NM; Simsek S; Conemans EB; T'Sjoen G; den Heijer M
    Eur J Endocrinol; 2020 Nov; 183(5):529-536. PubMed ID: 33071222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.